<DOC>
	<DOCNO>NCT00086931</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin capecitabine , work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Oxaliplatin capecitabine may make tumor cell sensitive radiation therapy may kill tumor cell . Giving chemotherapy radiation therapy surgery may shrink tumor remove . PURPOSE : This phase I/II trial study side effect best dose oxaliplatin capecitabine give together radiation therapy see well work treat patient undergo surgery locally advance cancer rectum . NOTE : *The phase I portion trial close 06/2005 . The best dose oxaliplatin capecitabine determine .</brief_summary>
	<brief_title>Oxaliplatin , Capecitabine , Radiation Therapy Treating Patients With Locally Advanced Cancer Rectum</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose neoadjuvant oxaliplatin capecitabine combine radiotherapy patient locally advance adenocarcinoma rectum . ( Phase I close accrual 06/2005 . ) - Determine rate complete pathological response patient treat regimen . Secondary - Determine overall survival patient treat regimen . - Determine rate local overall failure patient treat regimen . - Determine utility TS , TP , DPD , ERCC-1 , apoptosis predict response patient treat regimen . - Determine rate pathologic down-staging patient treat regimen . - Determine safety toxicity regimen patient . - Determine rate sphincter-saving rectal surgery patient treat regimen deem candidate abdominoperineal resection diagnosis . OUTLINE : This multicenter , phase I ( phase I close accrual 06/2005 ) , dose-escalation study oxaliplatin capecitabine follow phase II study . - Phase I ( close accrual 06/2005 ) : Patients undergo radiotherapy daily 5 day week 5.5 week receive oral capecitabine twice daily day radiotherapy administer . Beginning day 1 radiotherapy , patient also receive oxaliplatin IV 2 hour day 1 , 8 , 15 , 22 , 29 . Cohorts 3-6 patient receive escalate dos oxaliplatin capecitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients undergo radiotherapy receive capecitabine oxaliplatin phase I MTD . All patient undergo curative-intent surgery 6-8 week completion chemoradiotherapy . Patients follow every 3 month 3 year every 6 month 2 year . PROJECTED ACCRUAL : A total 31-40 patient ( 6-15 phase I [ phase I close accrual 06/2005 ] 25 phase II ) accrue study within 2 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma rectum Tumor involve distal 12 cm rectum ( anal verge ) Clinically stag endoscopic ultrasound one follow criterion : T3T4 disease Evidence lymph node involvement , define presence ≥ 1 enlarge perirectal lymph node ( ≥ 1 cm size ) No know distant metastasis PATIENT CHARACTERISTICS : Age 18 75 Performance status ECOG 01 OR Karnofsky 70100 % Life expectancy More 1 year Hematopoietic WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin normal AST ALT ≤ 2.5 time upper limit normal Renal Creatinine normal OR Creatinine clearance ≥ 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other Able receive oral medication No malignancy within past 5 year except nonmelanoma skin cancer No prior concurrent significant neuropathy No prior allergic reaction attribute compound similar chemical biological composition study drug No ongoing active infection No concurrent uncontrolled illness No psychiatric illness social situation would preclude study compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod contraception 3 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent granulocytestimulating factor Chemotherapy No prior chemotherapy Endocrine therapy Not specify Radiotherapy No prior pelvic radiotherapy Surgery Not specify Other No concurrent investigational agent No concurrent anticancer agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
</DOC>